Clinical Trials Logo

Anemia, Hemolytic, Autoimmune clinical trials

View clinical trials related to Anemia, Hemolytic, Autoimmune.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05676697 Terminated - Clinical trials for Autoimmune Hemolytic Anemia

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Start date: January 13, 2023
Phase: Phase 1
Study type: Interventional

This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second line therapy.

NCT ID: NCT05086744 Terminated - Clinical trials for Immune Thrombocytopenia (ITP)

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Start date: December 21, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

NCT ID: NCT05073458 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia (wAIHA)

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

PATHWAY
Start date: March 15, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

NCT ID: NCT04661033 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia (wAIHA)

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Start date: September 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objectives: - Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA - Part B: To evaluate the efficacy of the selected dose in adults with wAIHA Secondary Objectives: - Part A (Cohorts 2 and 3 only) - To evaluate the efficacy of isatuximab in adults with wAIHA - To evaluate the durability of response to isatuximab and time to response - To evaluate the impact of isatuximab treatment on fatigue Part B - To evaluate the safety and tolerability of isatuximab in adults with wAIHA - To evaluate the durability of response to isatuximab and time to response - To evaluate the impact of isatuximab treatment on fatigue Parts A (all Cohorts) and B - To evaluate the effect of isatuximab on markers of hemolysis - To characterize the pharmacokinetic profile of isatuximab in adults with wAIHA - To evaluate the immunogenicity of isatuximab

NCT ID: NCT04253236 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

ASCEND-WAIHA
Start date: August 11, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.

NCT ID: NCT03075878 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Start date: January 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.